Geneviève Mailhot1,2, Josée Lamarche2,3,4, Dany H Gagnon3,4,5. 1. 1Research Centre, CHU Sainte-Justine, Montreal, Quebec Canada. 2. 2Department of Nutrition, Université de Montréal, Montreal, Quebec Canada. 3. 3Center for Interdisciplinary Research in Rehabilitation (CRIR), Montreal, Quebec Canada. 4. 4Institut universitaire sur la réadaptation en déficience physique de Montréal of the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Centre-Sud-de-l'Ile-de-Montréal, Montreal, Quebec Canada. 5. 5School of Rehabilitation, Université de Montréal, Montreal, Quebec Canada.
Abstract
STUDY DESIGN: Prospective case series. OBJECTIVES: To assess the effectiveness and safety of two vitamin D3 repletion protocols given to individuals with spinal cord injury (SCI). SETTING: Publicly-funded intensive inpatient rehabilitation center, Montreal, Canada. METHODS: Thirty adults with recent SCI complete or incomplete sensorimotor impairments were recruited upon admission from designated regional SCI trauma centers. Participants with serum 25OHD ≤ 30 nmol/L were given 10,000 IU of weekly and 1000 IU of daily vitamin D3 for 36.8 ± 11.9 days (higher dose: HD). Subjects with serum 25OHD > 30 nmol/L received 1000 IU of daily vitamin D3 for 38.2 ± 11.6 days (lower dose: LD). Outcomes were changes in 25OHD levels from baseline to the end of the study period and safety outcomes. Thresholds for vitamin D deficiency, insufficiency and sufficiency were: 25OHD levels ≤30 nmol/L, 30-74 nmol/L, and ≥75 nmol/L. RESULTS: At baseline, 34 and 66% of participants had serum 25OHD < 30 and >30 nmol/L. Both protocols induced a rise in serum 25OHD with a greater increase in the HD vs. LD regimen (31.4 [95% CI: 16.7, 46.0] vs. 11.7 nmol/L [95% CI: 2.2, 21.2]). None of the participants given the HD remained vitamin D deficient, but only one achieved vitamin D sufficiency. Nearly all individuals on the LD regimen remained vitamin D insufficient with only two reaching vitamin D sufficiency. No adverse effects were observed over the course of the supplementation. CONCLUSIONS: Although 1000 IU of daily vitamin D3 alone or in combination with weekly 10,000 IU for an average of 37.6 days increased serum 25OHD, they were unsuccessful in improving the impaired vitamin D status during inpatient rehabilitation of individuals with a recent SCI.
STUDY DESIGN: Prospective case series. OBJECTIVES: To assess the effectiveness and safety of two vitamin D3 repletion protocols given to individuals with spinal cord injury (SCI). SETTING: Publicly-funded intensive inpatient rehabilitation center, Montreal, Canada. METHODS: Thirty adults with recent SCI complete or incomplete sensorimotor impairments were recruited upon admission from designated regional SCI trauma centers. Participants with serum 25OHD ≤ 30 nmol/L were given 10,000 IU of weekly and 1000 IU of daily vitamin D3 for 36.8 ± 11.9 days (higher dose: HD). Subjects with serum 25OHD > 30 nmol/L received 1000 IU of daily vitamin D3 for 38.2 ± 11.6 days (lower dose: LD). Outcomes were changes in 25OHD levels from baseline to the end of the study period and safety outcomes. Thresholds for vitamin D deficiency, insufficiency and sufficiency were: 25OHD levels ≤30 nmol/L, 30-74 nmol/L, and ≥75 nmol/L. RESULTS: At baseline, 34 and 66% of participants had serum 25OHD < 30 and >30 nmol/L. Both protocols induced a rise in serum 25OHD with a greater increase in the HD vs. LD regimen (31.4 [95% CI: 16.7, 46.0] vs. 11.7 nmol/L [95% CI: 2.2, 21.2]). None of the participants given the HD remained vitamin D deficient, but only one achieved vitamin D sufficiency. Nearly all individuals on the LD regimen remained vitamin D insufficient with only two reaching vitamin D sufficiency. No adverse effects were observed over the course of the supplementation. CONCLUSIONS: Although 1000 IU of daily vitamin D3 alone or in combination with weekly 10,000 IU for an average of 37.6 days increased serum 25OHD, they were unsuccessful in improving the impaired vitamin D status during inpatient rehabilitation of individuals with a recent SCI.
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: David Reid; Barry J Toole; Susan Knox; Dinesh Talwar; Johann Harten; Denis St J O'Reilly; Scott Blackwell; John Kinsella; Donald C McMillan; A Michael Wallace Journal: Am J Clin Nutr Date: 2011-03-16 Impact factor: 7.045
Authors: Jenna Louise Waldron; Helen L Ashby; Michael P Cornes; Julia Bechervaise; Cyrus Razavi; Osmond L Thomas; Sanjiv Chugh; Shreeram Deshpande; Clare Ford; Rousseau Gama Journal: J Clin Pathol Date: 2013-03-01 Impact factor: 3.411